Sickle Cell Disease Drugs Market Segmentation:
Drug Class Segment Analysis
Gene therapy is the dominant segment that is expected to hold a market share of 38.5% by 2037. The approval received from the Food and Drug Administration and European Medical Agency for Casgevy and Lyfgenia led to high adoption in the market. The Efficacy of the drug with one-time dosing ensured a better outcome for the sickle cell disease treatment. According to the National Institute of Health, it is projected that the high price point of the gene therapy drug will elevate the revenue accumulation rate in the global market.
Mechanism Action Segment Analysis
The haemoglobin polymerization inhibitors segment is expected to hold a considerable market share by 2037. According to the report of the World Health Organization, hydroxyurea adoption is expanding at a faster scale in the emerging market. Production cost of hydroxyurea is comparatively low in India and Africa as comparison to the US and EU markets. Approximately USD 48 /year is the manufacturing cost of hydroxyurea in India, which is USD 990/year in the U.S. This led to the quick adoption of hydroxyurea and promoted the growth of haemoglobin polymerization inhibitors.
Our in-depth analysis of the global sickle cell disease drugs market includes the following segments:
|
Segment |
Subsegment |
|
Drug Class |
|
|
Mechanism of Action |
|
|
Distribution Channel |
|
